相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression
Daniel Rathkey et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
BAP1: role in carcinogenesis and clinical implications
Daniel A. Kobrinski et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee T. Keung et al.
JOURNAL OF CLINICAL MEDICINE (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
PARP inhibition - opportunities in pancreatic cancer
Shubham Pant et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
Taku Fujimura et al.
CANCERS (2019)
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2018)
PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Dalia Kamel et al.
CURRENT DRUG TARGETS (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Sanghamitra Mylavarapu et al.
FRONTIERS IN ONCOLOGY (2018)
Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma
K. G. Ewens et al.
BMC CANCER (2018)
Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma
Babak Masoomian et al.
JOURNAL OF CURRENT OPHTHALMOLOGY (2018)
Emerging role of precision medicine in biliary tract cancers
James M. Bogenberger et al.
NPJ PRECISION ONCOLOGY (2018)
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
Rossella Parrotta et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
Mansi Parasramka et al.
MOLECULAR CANCER (2017)
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Angela Bononi et al.
NATURE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis
Amir A. Rahnemai-Azar et al.
SURGICAL ONCOLOGY-OXFORD (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Nader N. Massarweh et al.
CANCER CONTROL (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini et al.
CLINICAL CANCER RESEARCH (2016)
Cohesin mutations in human cancer
Victoria K. Hill et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2016)
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
Juliana Andrici et al.
MEDICINE (2016)
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism
Joshua M. Baughman et al.
CELL REPORTS (2016)
Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity
Akihiro Fujimoto et al.
NATURE COMMUNICATIONS (2015)
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Daniela Sia et al.
NATURE COMMUNICATIONS (2015)
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
Michele Carbone et al.
PLOS GENETICS (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Jinfei Xu et al.
CANCER RESEARCH (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Supriya K. Saha et al.
NATURE (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mutational landscape of intrahepatic cholangiocarcinoma
Shanshan Zou et al.
NATURE COMMUNICATIONS (2014)
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
Michele Simbolo et al.
ONCOTARGET (2014)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad et al.
PLOS GENETICS (2014)
Chromosome 3 Status Combined With BAP1 and EIF1AX Mutation Profiles Are Associated With Metastasis in Uveal Melanoma
Kathryn G. Ewens et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia et al.
GASTROENTEROLOGY (2013)
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers
Waraporn Chan-on et al.
NATURE GENETICS (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
S. Postel-Vinay et al.
ONCOGENE (2013)
Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma
Mitchell Cheung et al.
CANCER GENETICS (2013)
Beyond DNA repairs additional functions of PARP-1 in cancer
Alice N. Weaver et al.
FRONTIERS IN ONCOLOGY (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
O-GlcNAc Transferase/Host Cell Factor C1 Complex Regulates Gluconeogenesis by Modulating PGC-1α Stability
Hai-Bin Ruan et al.
CELL METABOLISM (2012)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Zhigang C. Wang et al.
CLINICAL CANCER RESEARCH (2012)
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Michele Carbone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Pena-LlopiS et al.
NATURE GENETICS (2012)
Sister Chromatid Cohesion
Jan-Michael Peters et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
An Emerging Model for BAP1's Role in Regulating Cell Cycle Progression
Ziad M. Eletr et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2011)
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Mohamed H. Abdel-Rahman et al.
JOURNAL OF MEDICAL GENETICS (2011)
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu et al.
PLOS ONE (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1
Yuichi J. Machida et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization
Karen H. Ventii et al.
CANCER RESEARCH (2008)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
HE Bryant et al.
NUCLEIC ACIDS RESEARCH (2006)
We of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage
K Yoshida et al.
CANCER SCIENCE (2004)
分享论文
